Formidable Defenses In Utero
Maternal fetal immunotolerance has been puzzling scientists for years. A developing human embryo encounters a multitude of threatening scenarios in the womb, and normally, its immune system can win these battles outright. Exposed to a variety of non-inherited antigens derived from the mother's cells (semiallogeneic antigens), amniotic fluid, pathogens, or food, the fetus must fight. But how does it defend itself throughout gestation? And what do we do when protection fails? A new study by McGovern et al. (2017) provides remarkable insight into this poorly understood phenomenon.
You will recognize this friendly immune cell population: your garden-variety antigen-presenting cells (APC). They are key enablers of self-tolerance, also capable of priming allogeneic T cells, yet they are quite spectacular: APCs from a fetus might be more Jedi-like than those from an adult. Indeed, systematic analysis of APCs from second-trimester human fetal tissues (16-22 weeks of estimated gestation age) has unveiled unique functional characteristics of conventional dendritic cells (DC)-a subset of APCs-unlike those of adult DCs (McGovern et al., 2017) . They can do what adult DCs can: migrate to draining lymph nodes and skin and sense danger signals (e.g., pathogens) via Toll-like Receptor (TLR) recognition. However, in the grand scheme of things, they are different from adult DCs, bearing a penchant for immunosuppression. A combination of gene arrays and flow cytometry has revealed that fetal DCs induce more immunosuppressive and tolerogenic regulatory T cells (Treg) than adult DCs. Co-cultured in vitro, they curb the proinflammatory and proliferative capacity of allogeneic T cells (McGovern et al., 2017) . For the fetus, the balance a priori may be tilted toward a scenario of ''defend and tolerate'' rather than ''kill'' (at least during this time window).
Despite clear similarities, more than 3,000 genes are differentially expressed in fetal and adult DCs (mostly in inflammatory and immune pathways); now, we know that arginase-2 is highly expressed in fetal DCs (McGovern et al., 2017) . This is relevant because arginase depletes L-arginine from the milieu, blunting tumor necrosis factor (TNF) production and innate immune responses (Morris, 2010 , McGovern et al., 2017 . In addition, arginase and TNF are important in mediating immunosuppression in newborns (Elahi et al., 2013; Morris, 2010) . Thus, the immunosuppressive prowess of the fetus and neonate likely endows them with an immunological advantage that enables tolerance. Conceptually, these findings are consistent with a number of studies. For instance, in utero exposure to malaria leads to Treg expansion in the human fetus, even though it can negatively impact the neonate by resulting in tolerance to malaria (Prahl et al., 2016) . Because fetal effector T cell expansion in response to malaria has also been reported (Prahl et al., 2016) , it remains unclear how the timing of exposure can affect the balance between immunosuppressive and cytotoxic responses in the fetus.
The implications from these studies are far-reaching in that presumably, the fetal immune system harbors great plasticity, illustrated by highly dynamic temporal responses. It will be quite interesting to elucidate how and when adaptation to specific conditions in utero shape the fetal immune system; will this adaptation lead to transient or life-long changes in the newborn's immune system? For example, what role does arginine metabolism play for different immune cell subsets in the fetus and the neonate? Indeed, recent findings have demonstrated that L-arginine levels can regulate various metabolic pathways in T cells (Geiger et al., 2016) . Another emerging question is how microbial attack and TLR stimulation trumps fetus-induced immunosuppression: when protective mechanisms fail in the fetus, what means can be sought to counter the potentially deleterious effects of invading pathogens? And when a balance between immunosuppression and cytotoxicity is critical at any given point in time (though not necessarily an either-or question), what interventions-if any-might be envisaged to ensure a healthy pregnancy outcome? Clearly, in cases of prenatal Zika virus or cytomegalovirus infections, these queries warrant utmost attention.
Maternal-fetal communication is crucial, and various regulatory mechanisms, including immunotolerance, epigenetic modifications, programming, and others (many remain undefined) have been undoubtedly instated to ensure the health of the developing embryo (Arck and Hecher, 2013) . Presently, the assessment of cross-talk pathways and key events at the fetomaternal interface stands out as a priority; research in these areas should allow us to gain further insight into the pathogenesis and management of pregnancy complications and infections and to better gauge postnatal outcomes.
